Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company''s lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer''s disease (AD) and Parkinson''s disease, as well as is in clinical trials for Alzheimer''s disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Latest shares articles
Trading Nasdaq 100’s fresh record high
Progress on the trade front, easing geopolitical tensions, and ‘revenge tax’ removed sees risk appetite improve.
11:02, 30 June 2025
Capital.com expands industry engagement as it joins Innovate Finance and the London Chamber of Commerce and Industry
Memberships signify commitment to actively participate in the development and transformation of the UK’s financial and technology sectors.
09:11, 30 June 2025
Capital.com enhances EU Client protection with up to 1 million euro insurance cover
Capital.com announced the launch of a new enhanced insurance scheme specifically for clients across the European Union (EU).
09:13, 26 June 2025
Buffett’s cash pile just got even larger
Warren Buffett just announced he's stepping down as CEO of Berkshire Hathaway – and he's leaving his successor a massive pile of cash. Since 2024, Buffett has sold off a massive amount of stock, more than doubling Berkshire's cash position from $167bn to $348bn.
18:05, 25 June 2025
Ratings and Reviews
Ratings and Reviews
